Depomed builds market share and enhances its revenue stream through two forms of strategic partnerships:
- The company out-licenses internally developed drugs to commercialization partners worldwide (often while retaining rights in selected countries/market segments);
- Depomed also collaborates with companies looking to utilize Acuform® delivery technology to enhance their own pharmaceutical products.
A commercialization agreement was signed on December 2017 for the U.S. commercialization rights to NUCYNTA® ER and NUCYNTA® for the management of pain.
A promotion agreement was established in July 2008 for the U.S. commercialization of Glumetza (metformin hydrochloride extended release tablets) for type 2 diabetes mellitus.
A license agreement was established in March 2011 granting Boehringer Ingelheim worldwide rights to Acuform delivery technology for the development and commercialization of certain fixed dose combination product(s) which include extended release metformin and proprietary Boehringer Ingelheim compound(s) in development for type 2 diabetes.
A license and development agreement was established in November 2008 granting Mallinckrodt an option to license Acuform delivery technology to develop and commercialize up to four pharmaceutical products.
A license agreement was established in August 2010 granting Janssen Pharmaceutica worldwide rights to Acuform delivery technology for the development of a fixed dose combination formulation of canagliflozin, a Sodium Glucose Transport 2 (SGLT2) inhibitor, and extended-release metformin.
To learn more about these partnerships, please visit the press release section of this website.
Depomed welcomes inquiries from companies interested in commercialization partnerships. To learn more, please contact the company’s business development department at firstname.lastname@example.org.